Ocugen (OCGN) said Tuesday that an independent safety board reviewed data from the first dosing group in its phase 1 trial of OCU200 for diabetic macular edema and approved advancing to the second group.
The company said the trial is testing OCU200, a fusion protein combining two human proteins, in patients receiving two doses six weeks apart.
Ocugen said it plans to complete the study in H2 and provide periodic updates on safety and efficacy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments